Regenxbio Capital Expenditures (CapEx) Growth & History (RGNX)
Regenxbio's capital expenditures (capex) was $2.4M for fiscal 2025.
View full Regenxbio company overviewRegenxbio annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.4M | −$22,000 | −0.90% |
| 2024 | 2024-12-31 | $2.4M | −$7.5M | −75.54% |
| 2023 | 2023-12-31 | $10.0M | −$20.8M | −67.58% |
| 2022 | 2022-12-31 | $30.7M | −$53.5M | −63.50% |
| 2021 | 2021-12-31 | $84.2M | $57.3M | +213.28% |
| 2020 | 2020-12-31 | $26.9M | $15.1M | +129.26% |
| 2019 | 2019-12-31 | $11.7M | −$1.6M | −11.73% |
| 2018 | 2018-12-31 | $13.3M | $6.1M | +85.45% |
| 2017 | 2017-12-31 | $7.2M | −$989,000 | −12.14% |
| 2016 | 2016-12-31 | $8.1M | $7.6M | +1461.11% |
| 2015 | 2015-12-31 | $522,000 | — | — |
Regenxbio quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $760,000 | $369,000 | +94.37% |
| Q1 2026 | 2026-03-31 | $1.2M | $211,000 | +20.61% |
| Q4 2025 | 2025-12-31 | $508,000 | −$571,000 | −52.92% |
| Q3 2025 | 2025-09-30 | $491,000 | $165,000 | +50.61% |
| Q2 2025 | 2025-06-30 | $391,000 | −$83,000 | −17.51% |
| Q1 2025 | 2025-03-31 | $1.0M | $467,000 | +83.84% |
| Q4 2024 | 2024-12-31 | $1.1M | −$47,000 | −4.17% |
| Q3 2024 | 2024-09-30 | $326,000 | −$1.1M | −77.35% |
| Q2 2024 | 2024-06-30 | $474,000 | −$2.1M | −81.61% |
| Q1 2024 | 2024-03-31 | $557,000 | −$4.3M | −88.44% |
| Q4 2023 | 2023-12-31 | $1.1M | −$4.3M | −79.41% |
| Q3 2023 | 2023-09-30 | $1.4M | −$3.6M | −71.50% |
| Q2 2023 | 2023-06-30 | $2.6M | −$6.7M | −72.10% |
| Q1 2023 | 2023-03-31 | $4.8M | −$6.1M | −56.07% |
| Q4 2022 | 2022-12-31 | $5.5M | −$9.1M | −62.57% |
| Q3 2022 | 2022-09-30 | $5.0M | −$13.6M | −72.99% |
| Q2 2022 | 2022-06-30 | $9.2M | −$10.6M | −53.45% |
| Q1 2022 | 2022-03-31 | $11.0M | −$20.1M | −64.65% |
| Q4 2021 | 2021-12-31 | $14.6M | $1.7M | +13.38% |
| Q3 2021 | 2021-09-30 | $18.7M | $12.6M | +207.94% |
| Q2 2021 | 2021-06-30 | $19.8M | $16.6M | +505.31% |
| Q1 2021 | 2021-03-31 | $31.0M | $26.4M | +570.00% |
| Q4 2020 | 2020-12-31 | $12.9M | $11.9M | +1150.15% |
| Q3 2020 | 2020-09-30 | $6.1M | $3.4M | +126.65% |
| Q2 2020 | 2020-06-30 | $3.3M | −$2.3M | −40.99% |
| Q1 2020 | 2020-03-31 | $4.6M | $2.2M | +88.59% |
| Q4 2019 | 2019-12-31 | $1.0M | −$3.9M | −78.91% |
| Q3 2019 | 2019-09-30 | $2.7M | −$693,000 | −20.55% |
| Q2 2019 | 2019-06-30 | $5.6M | $2.9M | +107.82% |
| Q1 2019 | 2019-03-31 | $2.5M | $111,000 | +4.74% |
| Q4 2018 | 2018-12-31 | $4.9M | $2.8M | +132.70% |
| Q3 2018 | 2018-09-30 | $3.4M | $2.9M | +649.33% |
| Q2 2018 | 2018-06-30 | $2.7M | $993,000 | +59.11% |
| Q1 2018 | 2018-03-31 | $2.3M | −$585,000 | −19.97% |
| Q4 2017 | 2017-12-31 | $2.1M | −$2.3M | −52.63% |
| Q3 2017 | 2017-09-30 | $450,000 | −$1.8M | −79.76% |
| Q2 2017 | 2017-06-30 | $1.7M | $605,000 | +56.28% |
| Q1 2017 | 2017-03-31 | $2.9M | $2.5M | +604.09% |
| Q4 2016 | 2016-12-31 | $4.4M | $4.3M | +3364.84% |
| Q3 2016 | 2016-09-30 | $2.2M | $2.1M | +2713.92% |
| Q2 2016 | 2016-06-30 | $1.1M | $866,000 | +414.35% |
| Q1 2016 | 2016-03-31 | $416,000 | $310,000 | +292.45% |
| Q4 2015 | 2015-12-31 | $128,000 | — | — |
| Q3 2015 | 2015-09-30 | $79,000 | — | — |
| Q2 2015 | 2015-06-30 | $209,000 | — | — |
| Q1 2015 | 2015-03-31 | $106,000 | — | — |
Regenxbio capital expenditures (capex) trends
Over the last five fiscal years, Regenxbio's capital expenditures (capex) decreased from $26.9M to $2.4M, a change of −$24.5M. The latest reported quarter, Q2 2026, shows $760,000.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regenxbio source filings ↗